Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature
Mook S, Knauer M, Bueno-de-Mesquita J, Retèl V, Wesseling J, Linn S, Van't Veer L, Rutgers E. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010; 17:1406-13.
Jan 22, 2010Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature
Jan 22, 2010Ann Surg Oncol 2010; 17:1406-13
Mook Stella, Knauer Michael, Bueno-de-Mesquita Jolien M, Retèl Valesca P, Wesseling Jelle, Linn Sabine C, Van't Veer Laura J, Rutgers Emiel J
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)
Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie 2010; 33:222-8.
Jan 1, 2010Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)
Jan 1, 2010Onkologie 2010; 33:222-8
Ruhstaller Thomas, Köberle Dieter, von Briel Christian, Lombriser Norbert, Lohri Andreas, Pederiva Stefanie, von Moos Roger, Thierstein Sandra, Borner Markus, Schuller Jan C, Ribi Karin, Templeton Arnoud, Popescu Razvan
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
von Moos R, Lanz D, Simcock M, Köberle D, Cathomas R, Uhlmann C, Widmer L, Ruhstaller T, Roth A, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie 2010; 33:295-9.
Jan 1, 2010Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
Jan 1, 2010Onkologie 2010; 33:295-9
von Moos Roger, Lanz Doris, Simcock Mathew, Köberle Dieter, Cathomas Richard, Uhlmann Catrina, Widmer Lucas, Ruhstaller Thomas, Roth Arnaud, Popescu Razvan
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer
Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer. Onkologie 2010; 33:222-228.
Jan 1, 2010Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer
Jan 1, 2010Onkologie 2010; 33:222-228
Ruhstaller Thomas, Köberle Dieter, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos Roger, Thierstein S, Borner M, Schuller J C, Ribi K, Templeton Arnoud, Popescu R
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Huober J, Lück H, Goehler T, Gerhardt S, Wischnik A, Schmidt M, Neise M, Nusch A, Fett W, Rost A. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC cancer 2010; 10:2.
Jan 1, 2010A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Jan 1, 2010BMC cancer 2010; 10:2
Huober Jens, Lück Hans-Joachim, Goehler Thomas, Gerhardt Steffen, Wischnik Arthur, Schmidt Marcus, Neise Michael, Nusch Arnd, Fett Werner, Rost Andreas
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
Costa S, Tesch H, Gerber B, Baumann K, Thomssen C, Breitbach G, Ibishi S, Jackisch C, Mehta K, Weiss E, Ataseven B, Loibl S, Kaufmann M, Zahm D, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J, von Minckwitz G. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:83-91.
Jan 1, 2010Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
Jan 1, 2010Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:83-91
Costa Serban Dan, Tesch Hans, Gerber Bernd, Baumann Klaus H, Thomssen Christoph, Breitbach Georg Peter, Ibishi Shaip, Jackisch Christian, Mehta Keyur, Weiss Erich, Ataseven Beyhan, Loibl Sibylle, Kaufmann Manfred, Zahm Dirk-Michael, Hilfrich Jörn, Huober Jens, Eidtmann Holger, du Bois Andreas, Blohmer Jens-Uwe, von Minckwitz Gunter
The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer
Huober J, Thürlimann B. The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer. Breast Care (Basel) 2009; 4:367-372.
Dec 16, 2009The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer
Dec 16, 2009Breast Care (Basel) 2009; 4:367-372
Huober Jens, Thürlimann Beat
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Klaeser B, Ruhstaller T, von Moos R, Albrecht S, Caspar C, Pestalozzi B, Zünd M, Brauchli P, Cescato-Wenger C, Hany T, Balmer-Majno S, Widmer L, Köberle D, Schuller J, Nitzsche E, Lange J. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009; 32:724-30.
Dec 1, 2009Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Dec 1, 2009Onkologie 2009; 32:724-30
Klaeser Bernd, Ruhstaller Thomas, von Moos Roger, Albrecht Susanne, Caspar Clemens, Pestalozzi Bernhard C, Zünd Michael, Brauchli Peter, Cescato-Wenger Corinne, Hany Thomas, Balmer-Majno Sabine, Widmer Lucas, Köberle Dieter, Schuller Jan C, Nitzsche Egbert, Lange Jochen
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V, Harter P. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2009; 21:370-5.
Nov 4, 2009A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
Nov 4, 2009Ann Oncol 2009; 21:370-5
du Bois A, Huober Jens, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V L, Harter P
Adjuvant! When the new world meets the old world
Huober J, Thürlimann B. Adjuvant! When the new world meets the old world. The Lancet 2009; 10:1028-9.
Nov 1, 2009Adjuvant! When the new world meets the old world
Nov 1, 2009The Lancet 2009; 10:1028-9
Huober Jens, Thürlimann Beat
Update of the BIG 1-98 Trial: where do we stand?
Jörger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we stand?. Breast 2009; 18 Suppl 3:S78-82.
Oct 1, 2009Update of the BIG 1-98 Trial: where do we stand?
Oct 1, 2009Breast 2009; 18 Suppl 3:S78-82
Jörger Markus, Thürlimann Beat
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009
Sep 12, 2009Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Sep 12, 2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009
Cathomas Richard, Köberle Dieter, Ruhstaller Thomas, Mayer Gisela, Räss Andrea, Mey Ulrich, von Moos Roger
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8.
Sep 1, 2009Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Sep 1, 2009Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8
Ruhstaller Thomas, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle Dieter, Balmermajno S, Pestalozzi B C, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J C, Widmer L, Swiss Group for Clinical Cancer Research (SAKK)
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489-98.
Sep 1, 2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Sep 1, 2009Ann Oncol 2009; 20:1489-98
Rabaglio M, Coates A S, Goldhirsch A, Gelber R D, Smith I, Láng I, Nogaret J-M, Pienkowski T, Colleoni M, Paridaens R J, Forbes J F, Campone M, Mouridsen H, Thürlimann Beat, Hawle H, Castiglione-Gertsch M, Price K N, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
Pagani O, Goldhirsch A, Coates A, Fey M, Collins J, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Gelber R, Price K, International Breast Cancer Study Group (IBCSG). Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009; 117:319-24.
Sep 1, 2009Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
Sep 1, 2009Breast Cancer Res Treat 2009; 117:319-24
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Fey Martin F, Collins John, Thürlimann Beat, Lindtner Jurij, Holmberg Stig B, Castiglione-Gertsch Monica, Gelber Richard D, Price Karen N, International Breast Cancer Study Group (IBCSG)
Some comments to the Pattern of Care Study
Thürlimann B. Some comments to the Pattern of Care Study. Schweiz. Krebsbulletin 2009; 3:212-212.
Sep 1, 2009Some comments to the Pattern of Care Study
Sep 1, 2009Schweiz. Krebsbulletin 2009; 3:212-212
Thürlimann Beat
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
BIG 1-98 Collaborative Group, Gelber R, Regan M, Price K, Forbes J, Mauriac L, Smith I, Paridaens R, Thürlimann B, Goldhirsch A, Giobbie-Hurder A, Mouridsen H, Coates A. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. NEJM 2009; 361:766-76.
Aug 20, 2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
Aug 20, 2009NEJM 2009; 361:766-76
BIG 1-98 Collaborative Group, Gelber Richard D, Regan Meredith M, Price Karen N, Forbes John F, Mauriac Louis, Smith Ian, Paridaens Robert, Thürlimann Beat, Goldhirsch Aron, Giobbie-Hurder Anita, Mouridsen Henning, Coates Alan S
ASCO 2009: What's New in Breast Cancer Therapy?
Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's New in Breast Cancer Therapy?. Breast Care (Basel) 2009; 4:268-271.
Aug 14, 2009ASCO 2009: What's New in Breast Cancer Therapy?
Aug 14, 2009Breast Care (Basel) 2009; 4:268-271
Biganzoli Laura, Bonnefoi Hervé, Cardoso Fatima, Coleman Robert, Thürlimann Beat
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
Goldhirsch A, Ingle J, Gelber R, Coates A, Thürlimann B, Senn H, Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319-29.
Aug 1, 2009Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
Aug 1, 2009Ann Oncol 2009; 20:1319-29
Goldhirsch A, Ingle J N, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, Panel members
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Pagani O, Goldhirsch A, Coates A, Forbes J, Murray E, Fey M, Thürlimann B, Lindtner J, Collins J, Crivellari D, Holmberg S, Gelber R, Price K, Castiglione-Gertsch M, Simoncini E, Gelber S, International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009; 116:491-500.
Aug 1, 2009Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Aug 1, 2009Breast Cancer Res Treat 2009; 116:491-500
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Forbes John F, Murray Elizabeth, Fey Martin F, Thürlimann Beat, Lindtner Jurij, Collins John, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Castiglione-Gertsch Monica, Simoncini Edda, Gelber Shari, International Breast Cancer Study Group